The hypoxia-inducible factor (HIF) pathway controls diverse aspects of the immunological response. Enhanced HIF activity is able to extend and potentiate the effector response of CD8+ T cells against chronic infections and tumor growth.
References
Wherry, E.J. Nat. Immunol. 12, 492–499 (2011).
Kao, C. et al. Nat. Immunol. 12, 663–671 (2011).
Shin, H. et al. Immunity 31, 309–320 (2009).
Doedens, A.L. et al. Nat. Immunol. 14, 1173–1182 (2013).
Dang, E.V. et al. Cell 146, 772–784 (2011).
Shi, L.Z. et al. J. Exp. Med. 208, 1367–1376 (2011).
Li, M. & Kim, W.Y. J. Cell. Mol. Med. 15, 187–195 (2011).
Wherry, E.J. et al. Immunity 27, 670–684 (2007).
Kaech, S.M. & Cui, W. Nat. Rev. Immunol. 12, 749–761 (2012).
Paley, M.A. et al. Science 338, 1220–1225 (2012).
Zhou, X. et al. Immunity 33, 229–240 (2010).
Baitsch, L. et al. J. Clin. Invest. 121, 2350–2360 (2011).
Zhou, Q. et al. Blood 117, 4501–4510 (2011).
Göthert, J.R. et al. Cancer Immunol. Immunother. (2013).
McNamee, E.N., Korns, J.D., Homann, D. & Clambey, E.T. Immunol. Res. 55, 58–70 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Göthert, J. Bypassing T cell 'exhaustion'. Nat Immunol 14, 1114–1116 (2013). https://doi.org/10.1038/ni.2742
Published:
Issue Date:
DOI: https://doi.org/10.1038/ni.2742
- Springer Nature America, Inc.